In This Article:
-
Quarterly Revenue: Approximately $40 million, slightly lower due to less sourcing of standard of care.
-
Cash Position: $175 million Norwegian Kroner, projected to fund operations until the third quarter of 2025.
Release Date: November 13, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
BerGenBio ASA (FRA:7BG0) has identified a significant unmet medical need in STK 11 mutated patients, presenting a substantial market opportunity.
-
The company has received a fast-track designation from the FDA for its treatment, indicating potential for expedited development and review.
-
BerGenBio ASA (FRA:7BG0) has a strong safety database, having studied its molecule in over 600 patients, which supports its ongoing clinical trials.
-
The company is leading efforts in addressing STK 11 mutated populations with its AXL inhibitor, positioning itself as a pioneer in this niche.
-
Financially, BerGenBio ASA (FRA:7BG0) is stable, with sufficient cash reserves projected to fund operations into the third quarter of 2025.
Negative Points
-
The company has faced administrative delays in some study sites, which could impact patient recruitment timelines.
-
BerGenBio ASA (FRA:7BG0) has discontinued its Sylvest program due to the lack of attractive partnership opportunities.
-
The ADC 601 program faced setbacks due to a narrow therapeutic window, leading to its discontinuation by ADC Therapeutics.
-
There is limited news flow between quarterly updates, which may cause concern among investors seeking more frequent updates.
-
The CEO, Martin Olin, is leaving the company, which could lead to uncertainties during the transition period until a new CEO is appointed.
Q & A Highlights
Q: When do you expect to present the interim data from the BTBC 16 study? A: The interim data is expected to be presented in the early part of 2025. However, an exact date cannot be provided as the data readout is not under our control.
Q: When will the complete data set from the phase two part be available? A: The final readout could be as late as 2026, as the study protocol commits to following patients for two years. The exact timing will depend on the data.
Q: Why was the work on Sylvester discontinued? A: In 2022, we decided to focus our strategy and discontinued internal efforts on Sylvester. Despite outreach efforts, no attractive partnership was found, leading to the program's closure.
Q: What was the reason for adding David Coldman to the board? A: David Coldman brings extensive experience in business development and licensing from pharmaceutical and biotech companies, which is a valuable addition to the board's competencies.